Houston, TX - April 26, 2011. ?SpectraCell Laboratories has officially been granted a license to provide its Lipoprotein Particle Profile ? (LPP ?) test, which assesses cardiovascular risk, to New York state physicians and patients. ?The recently patented LPP ? test has been commercially available to the other 49 states since 2006. SpectraCell began the process of acquiring a licensure in 2008 with an application submission the state of New York. ? The laboratory underwent an initial inspection ...
Houston, TX - February 7, 2011. ?SpectraCell Laboratories has recently been awarded a patent on their Lipoprotein Particle Profile ? (LPP ?) test which is used to measure cardiovascular risk. ? The LPP ? has been commercially available since 2006, and is a type of advanced cholesterol test that measures lipoprotein subgroups. ? The LPP ? gives more accurate estimation of cardiovascular risk compared to a routine cholesterol test. ? The patent was awarded for use of a ?Method for Analyzing ...
Houston, TX- November 18, 2010. SpectraCell Laboratories now offers a test for the MTHFR gene, which is associated with elevated levels of the toxic amino acid homocysteine. Individuals with specific mutations of the MTHFR (methylenetetrahydrofolate reductase) gene have a much higher risk for heart disease, stroke and dementia due to high levels of homocysteine in their blood. MTHFR is an enzyme responsible for the proper metabolism of the harmful amino acid homocysteine into the ...
PR Categories
Go to Profile
Mark as Read